Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs

Pharmacology and Therapeutics

Volumn 90, Issue 2-3, 2001, Pages 231-259

  Joyce, Jeffrey N ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Caudate putamen; Islands of Calleja; Limbic; Nucleus accumbens; Striatum

Indexed keywords

2 DIPROPYLAMINO 1,2,3,4 TETRAHYDRO 6 (4 METHOXYPHENYLSULFONYLMETHYL)NAPHTHALENE; 2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 4 (4 CHLOROPHENYL) 1 (1H INDOL 3 YLMETHYL)PIPERIDIN 4 OL; 5 METHOXY 1 METHYL 2 PROPYLAMINOTETRALIN; 7 DIPROPYLAMINO 2,3,5,6,7,8 HEXAHYDRONAPHTHO[2,3 B]FURAN; ANTIPARKINSON AGENT; APOMORPHINE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; LEVODOPA; N [4 (8 CYANO 1,3A,4,9B TETRAHYDRO 3H-BENZOPYRANO[3,4 C]PYRROLE 2 YL)BUTYL] 4 PHENYLBENZAMIDE; NAFADOTRIDE; NEUROLEPTIC AGENT; QUINPIROLE; ROPINIROLE; SB 271011 A; U 99294; UNCLASSIFIED DRUG; DOPAMINE 2 RECEPTOR; DRD3 PROTEIN, HUMAN;

BRAIN REGION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; HUMAN; MOLECULAR CLONING; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SLEEP DISORDER; TARDIVE DYSKINESIA; ANIMAL; BRAIN; DRUG DELIVERY SYSTEM; GENETICS; PHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; PARKINSON DISEASE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA;

EID: 0034741123     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(01)00139-5     Document Type: Review

References (273)

1. Frequency of dementia in Parkinson disease
2. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort
3. Basal ganglia-thalamocortical circuits: Parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions
4. Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates
5. Role of Bcl-2 in the brain-derived neurotrophic factor survival response
6. Regulation by dopaminergic neurotransmission of dopamine D2 mRNA and receptor levels in the striatum and nucleus accumbens of the rat
7. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease
8. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]raclopride
9. Dopamine receptor distribution in the rat CNS: Elucidation using anti-peptide antisera directed against D1A and D3 subtypes
10. Acute and chronic administration of the selective D3 receptor antagonist SB-277011-A alters activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study
11. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194
12. Pramipexole - A new dopamine agonist for the treatment of Parkinson's disease
13. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys
14. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy
15. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa
16. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats
17. 3 receptor agonists
18. 3 knock-out and wild-type mice
19. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine D2 receptor mRNA
20. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
21. Clozapine, haloperidol, and the D4 antagonist PNU-101387G: In vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release
22. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography
23. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
24. 125I](R)-trans-7-hydroxy-2-[N-propyl-N-(3′-iodo-2′- propenyl)amino] tetralin binding to dopamine D3 receptors in rat olfactory tubercle
25. Lack of discrimination by agonists for D2 and D3 dopamine receptors
26. D3 receptor test in vitro predicts decreased cocaine self-administration in rats
27. Patterns of gene expression and behavior induced by chronic dopamine treatments
28. Differential effects of limbic versus striatal dopamine loss on motoric function
29. The case for neuroprotection with dopamine agonists
30. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole
31. D3-mediated alterations in mesencephalic derived neurotrophic activity
32. An evaluation of the role of mitochondria in neurodegenerative diseases: Mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration
33. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion
34. 2 dopamine receptors
35. Molecular diversity of the dopamine receptors
36. D1 dopamine receptor - The search for a function: A critical evaluation of the D1/D2 dopamine receptor classification and its functional implications
37. Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: Evidence of compensatory plasticity in nigrostriatal neurons
38. Free radicals, oxidative stress and neurodegeneration
39. 4.4 receptors expressed in Chinese hamster ovary cells
40. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
41. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
42. Expression of rat striatal D1 and D2 dopamine receptor mRNAs: Ontogenetic and pharmacological studies
43. Dopamine receptor mRNA expression patterns by opioid peptide cells in the nucleus accumbens of the rat: A double in situ hybridization study
44. Human dopamine D3 receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism
45. Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists
46. Differential effects of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex
47. Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand
48. Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment
49. Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: Comparison with quinpirole and apomorphine
50. Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: A combined in vivo electrophysiological and microdialysis study
51. Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: A combined in vivo electrophysiological and microdialysis study
52. Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain
53. 3 receptors expressed by all mesencephalic dopamine neurons
54. Oral stereotypy induced by amphetamine microinjection into striatum: An anatomical mapping study
55. Alterations in nigrostriatal dopaminergic function within BDNF mutant mice
56. 3 receptor mRNA
57. Meta-analysis of DRD3 gene and schizophrenia: Ethnic heterogeneity and significant association in Caucasians
58. Clinical features predicting dementia in idiopathic Parkinson's disease: A follow-up study
59. Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias
60. Central administration of dopamine D3 receptor antisense to rat: Effects on locomotion, dopamine release and [3H]spiperone binding
61. Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: An autoradiographic study
62. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part I
63. Native human neocortex release-regulating dopamine D2 type autoreceptors are dopamine D2 subtype
64. The effect of haloperidol on D2 dopamine receptor subtype mRNA levels in the brain
65. Dopamine receptor subtypes: Differential regulation after 8 months treatment with antipsychotic drugs
66. The effects of haloperidol on dopamine receptor gene expression
67. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
68. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors
69. 2long dopamine receptors expressed in recombinant cells
70. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons
71. D1 and D2 dopamine receptor function in the striatum: Coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons
72. 7-OH-DPAT injected into the accumbens reduces locomotion and sucrose ingestion: D3 autoreceptor-mediated effects?
73. Antioxidant enzymes in the brain of zitter rats: Abnormal metabolism of oxygen species and its relevance to pathogenic changes in the brain of zitter rats with genetic spongiform encephalopathy
74. Dopamine D1/D2 agonists injected into nucleus accumbens and ventral pallidum differentially affect locomotor activity depending on site
75. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: In situ hybridization histochemical analysis
76. Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia
77. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis)
78. Dopamine D3 receptor gene: Organization, transcript variants, and polymorphism associated with schizophrenia
79. Apomorphine protects against MPTP-induced neurotoxicity in mice
80. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity
81. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization
82. Receptor mechanisms mediating clozapine-induced c-fos expression in the forebrain
83. Phenotypic characterization of neuroleptic-sensitive neurons in the forebrain: Contrasting targets of haloperidol and clozapine
84. Alterations in the cortical serotonergic system in schizophrenia: A postmortem study
85. 2 receptor expressing neurons
86. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study
87. Developmental regulation of expression of the D3 dopamine receptor in rat nucleus accumbens and islands of Calleja
88. Dopamine D2 receptor density remains constant in treated Parkinson's disease
89. The concept of the ventral striatum in nonhuman primates
90. 3 receptor agonist/antagonist in primate model of Parkinson's disease
91. Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone
92. Pramipexole-induced somnolence and episodes of daytime sleep
93. The subcortical projections of the allocortex: Similarities in the neural associations of the hippocampus, the piriform cortex, and the neocortex
94. Ropinirole and pramipexole, the new agonists
95. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test
96. Biochemical aspects of Parkinson's disease
97. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease
98. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist
99. Dopamine D2 agonist-induced behavioural depression is reversed by dopamine D1 agonists
100. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway
101. Post mortem studies in Parkinson's disease - Is it possible to detect brain areas for specific symptoms?
102. Clinico-pathological correlations in Parkinson's disease
103. Subdivisions of the dopamine-containing A8-A9-A10 complex identified by their differential mesostriatal innervation of striosomes and extrastriosomal matrix
104. Trend for an association between schizophrenia and D3S1310, a marker in proximity to the dopamine D3 receptor gene
105. Multiple dopamine receptors and behavior
106. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system
107. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatment
108. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases
109. 3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: Influence of withdrawal period
110. D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics
111. Linking the family of D2 receptors to neuronal circuits in human brain: Insights into schizophrenia
112. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density
113. Organization of dopamine D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia
114. 3 receptor number with degeneration of the mesostriatal dopamine system
115. Ventral striatal D3 receptors and Parkinson's disease
116. 3 receptors
117. 3 receptors
118. Dopamine transmission in the initiation and expression of drug and stress induced sensitization of motor activity
119. Multiple receptors for dopamine
120. Differential regional and cellular distribution of dopamine D2-like receptors: An immunocytochemical study of subtype-specific antibodies in rat and human brain
121. Dose-dependent effects of the D3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning
122. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice
123. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells
124. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice
125. Effects of dopamine and L-DOPA on survival of PC12 cells
126. Chronic eticlopride and dopamine denervation induce equal nonadditive increases in striatal D2 receptor density: Autoradiographic evidence against the dual mechanism hypothesis
127. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments
128. Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography
129. Neuroprotection by dopamine agonists
130. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis
131. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
132. D3 and D2 dopamine receptors: Visualization of cellular expression patterns in motor and limbic structures
133. The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies
134. D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment
135. D1 and D2 dopamine receptor gene expression in the rat striatum: Sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum
136. Expression of the D3 dopamine receptor in peptidergic neurons of the nucleus accumbens: Comparison with the D1 and D2 dopamine receptors
137. Dopamine receptor gene expression by enkephalin neurons in rat forebrain
138. Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene
139. Differential sensitivity of [3H]7-OH-DPAT-labeled binding sites in rat brain to inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline
140. The D3 dopamine receptor: Neurobiology and potential clinical relevance
141. 3 receptors. Relevance for the drug treatment of Parkinson's disease
142. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons
143. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat
144. Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states
145. Lack of autoreceptor-mediated inhibitory control of dopamine release in striatal synaptosomes of D2 receptor-deficient mice
146. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity
147. Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures
148. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures
149. Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats
150. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets
151. Expression of D1 receptor, D2 receptor, substance P and enkephalin messenger RNAs in the neurons projecting from the nucleus accumbens
152. The organization of midbrain projections to the ventral striatum in the primate
153. The organization of midbrain projections to the striatum in the primate: Sensorimotor-related striatum versus ventral striatum
154. Antidepressant effects of pramipexole, a novel dopamine receptor agonist
155. The anticataleptic effect of 7-OH-DPAT: Are dopamine D3 receptors involved?
156. 35S-binding
157. Dopamine D2-receptor mRNA level in rat striatum after chronic haloperidol treatment
158. An estimate of the prevalence of dementia in idiopathic Parkinson's disease
159. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender
160. 4 dopamine receptors in HEK293 cells
161. A neurochemical and behavioral investigation of the involvement of nucleus accumbens dopamine in instrumental avoidance
162. Nigral cell loss produced by infusion of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
163. Dopamine receptor mRNA expression in human striatum and neocortex
164. Depletion of dopamine in the nucleus accumbens prevents the generation of locomotion by metabotropic glutamate receptor activation
165. 3 receptor knockdown through antisense oligonucleotide administration supports its inhibitory role in locomotion
166. 4 receptors
167. 2 receptors elicits prolactin secretion and catalepsy
168. 3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats
169. 3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626
170. 3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626
171. Dopamine receptors: From structure to function
172. Influence of dopamine on limbic inputs to the nucleus accumbens
173. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study
174. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease
175. Restless legs syndrome improved by pramipexole: A double-blind randomized trial
176. Cellular responses to psychomotor stimulant and neuroleptic drugs are abnormal in mice lacking the D1 dopamine receptor
177. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Correction with chronic administration of L-3,4-dihydroxyphenylalanine
178. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: Effects of MPTP and dopamine agonist replacement therapies
179. 3 receptors induces c-fos expression in primary cultures of rat striatal neurons
180. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part II
181. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice
182. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions
183. 2 receptors to mesostriatal regions of human forebrain
184. Dopamine receptors in the ventral pallidum regulate circling induced by opioids injected into the ventral pallidum
185. Electrophysiological verification of the presence of D1 and D2 dopamine receptors within the ventral pallidum
186. Motoric analysis of dopamine receptor subtype activation within the ventral pallidum and dorsal globus pallidus
187. The neural mechanisms and progressive nature of symptoms of Parkinson's disease-based on clinical, neurophysiological and morphological studies
188. 35S]thio)-triphosphate binding and antibody study
189. Dopamine D3 receptor antisense influences dopamine synthesis in rat brain
190. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset
191. Waking up to sleep episodes in Parkinson's disease
192. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop
193. Pramipexole vs levodopa as initial treatment for parkinson disease: A randomized controlled trial
194. Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets
195. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors
196. Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade
197. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease
198. Striatal dopaminergic markers in dementia with lewy bodies, Alzheimer's and Parkinson's diseases: Rostrocaudal distribution
199. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: A [123I]-IBZM SPET study
200. Spatial localization in the Morris water maze in rats: Acquisition is affected by intra-accumbens injections of the dopaminergic antagonist haloperidol
201. Alterations in D3 receptors in monkey caudate after MPTP and L-dopa treatments
202. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats
203. 3 dopamine receptors
204. The mechanims for the rapid neuroprotective effects of pramipexole against MPP+ in SH-SY5Y cells
205. Lesions of mouse striatum induced by 6-hydroxydopamine differentially alter the density, rate of synthesis, and level of gene expression of D1 and D2 dopamine receptors
206. 3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: Effect of levodopa treatment
207. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
208. 3 receptor antagonist, SB-277011-A
209. The effect of chronic L-dopa administration on supersensitive pre- and postsynaptic dopaminergic receptors in rat brain
210. Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum
211. The distribution of dynorphinergic terminals in striatal target regions in comparison to the distribution of substance P-containing and enkephalinergic terminals in monkeys and humans
212. Regional quantification of D1, D2, and D3 dopamine receptor mRNA in rat brain using a ribonuclease protection assay
213. The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine
214. Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: Opposite and synergistic functional interactions
215. Nigral degeneration in Parkinson's disease in relation to clinical features
216. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease
217. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys
218. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis
219. 2 receptor mRNA in rat striatum by chronic neuroleptic treatment
220. 2 receptor is elevated in the striatum of Parkinson's disease
221. Complex motor and sensorimotor functions of striatal and accumbens dopamine: Involvement in instrumental behavior processes
222. Behavioral functions of nucleus accumbens dopamine: Empirical and conceptual problems with the anhedonia hypothesis
223. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality
224. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables
225. 4 receptor antagonists
226. A functional test identifies dopamine agonists selective for D3 versus D2 receptors
227. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents
228. Asymmetrical pre-synaptic and post-synaptic changes in the striatal dopamine projection in dopa naive parkinsonism. Diagnostic implications of the D2 receptor status
229. D1/D3 receptor relationships in brain coexpression, coactivation, and coregulation
230. 3 receptor in schizophrenia and in antipsychotic drug actions
231. 2 receptor messenger RNA levels in the nucleus accumbens and caudate-putamen in rats
232. Antipsychotic drug doses and neuroleptic/dopamine receptors
233. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases
234. Dopamine D3 receptor gene not associated with symptomatology of major psychoses
235. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
236. ABT-431: The diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: In vitro characterization and effects in animal models of Parkinson's disease
237. Induction of c-fos and zif/268 gene expression in rat striatal neurons, following stimulation of D1-like dopamine receptors, involves protein kinase A and protein kinase C
238. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics
239. 3) as a novel target for antipsychotics
240. Increased rewarding properties of morphine in dopamine-transporter knockout mice
241. 125I]7-OH-PIPAT: Evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals
242. Differential regulation of dopamine D2 and D3 receptors by chronic drug treatments
243. Depression in classic versus akinetic-rigid Parkinson's disease
244. Behavioural synergism between the dopamine agonists SKF 38393 and LY 171555 in dopamine-depleted mice: Antagonism by sulpiride reveals only stimulant postsynaptic D-2 receptors
245. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1
246. Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release
247. Differential behavioral responses to dopaminergic stimulation of nucleus accumbens subregions in the rat
248. 2 receptors
249. Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole
250. The occurrence of depression in Parkinson's disease. A community-based study
251. Risk factors for depression in Parkinson disease
252. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment
253. 3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo
254. Evidence to suggest that agonist modulation of hyperlocomotion is via post-synaptic dopamine D2 or D3 receptors
255. Age-related degeneration of the serotoninergic fibers in the zitter rat brain
256. Age-related dopamine deficiency in the mesostriatal dopamine system of zitter mutant rats: Regional fiber vulnerability in the striatum and the olfactory tubercle
257. Effects of 7-hydroxy-N,N-di-n-propylaminotetralin on behaviour and blood pressure of spontaneously hypertensive rats
258. 3 receptors in Chinese hamster ovary cells
259. 3 receptor antisense attenuates leveodopa-induced behavioural sensitization in rats
260. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
261. 1 receptor agonists. The way forward for the treatment of Parkinson's disease?
262. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?
263. 3 dopamine receptor mRNA by neuroleptics
264. Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour
265. 3 dopamine receptors
266. Interactive effects of stimulation of D1 and D2 dopamine receptors on fos-like immunoreactivity in the normosensitive rat striatum
267. Functional recovery after destruction of dopamine systems in the nucleus accumbens of rats. I. Behavioral and biochemical studies
268. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors
269. Dopamine D3 receptor mutant and wild-type mice exhibit identical responses to putative D3 receptor-selective agonists and antagonists
270. Differential effects of dopamine antagonists on evoked dopamine release from slices of striatum and nucleus accumbens in rats
271. o subtype of G proteins in SH-SY5Y cells
272. 3 receptors in rat brain: Selective protection by dopamine
273. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice